Are there feasible prospects for manuka honey as an alternative to conventional antimicrobials?
Financial & competing interest disclosure

R Cooper has received grants from the British Society for Antimicrobial Chemotherapy, the Society for General Microbiology, the European Wound Management Association, the University of Waikato (in collaboration with the National Honey Board), the Waterloo Foundation, the UWIC Foundation and the Sir Halley Stewart Trust. Sponsorship to attend scientific meetings has been received from Capilano, Derma Sciences Inc. and Molnlycke; consultancy has been undertaken for Aspen Medical, Brightwake Ltd, Comvita UK, Derma Sciences Inc., Medlock Medical and Medihoney. Remuneration for presentations has been received from the Tissue Viability Society, American Professional Wound Care Association, Derma Sciences Inc., Comvita UK, World Union of Wound Healing Societies, North American Center for Continuing Medical Education and numerous beekeeping organizations. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.